In this section, we review the literature on psychosocial and pharmacological PTSD treatments delivered in the context of TBI.
Psychosocial Interventions for PTSD
Prior to reviewing the literature on cognitive-behavioral therapy (CBT) for PTSD in patients with TBI, it is important to first understand what CBT encompasses. CBT interventions, by definition, have a cognitive emphasis. They differ, however, from cognitive rehabilitation, which targets enhancement or restoration of specific cognitive skills (e.g., attention, executive functioning, memory) and/or compensatory strategies. CBT, in contrast, targets a change in the content of thoughts and in the emotions associated with those thoughts and/or memories of the trauma. Interventions involving exposure to the trauma memory and/or cognitive restructuring have a particularly strong evidence base for treatment of PTSD.
Psychosocial treatments for PTSD, however, were not originally designed with TBI or comorbid chronic cognitive deficits in mind. Exposure-based interventions involve repeated exposure to trauma memories and their reminders with the goal of habituation and modifying memories to form new emotional associations, a process that may be affected by the presence of posttraumatic amnesia in moderate to severe TBI. Cognitive restructuring involves reappraisal of maladaptive thoughts related to the trauma with the goal of considering alternative appraisals of the trauma and its consequences. As such, the patient must have the capacity to inhibit unconstructive automatic responses and the mental flexibility to consider alternatives, both aspects of cognition that can be compromised in the early stages of mild TBI
43 and persist in more severe TBIs.
44 Further, it is possible that persisting memory, attentional, and executive difficulties associated with TBI could interfere with the patient’s ability to engage in, or adhere to, treatment (e.g., attending to session content and remembering to complete homework assignments).
45 Thus, in considering PTSD interventions in the context of TBI, we take into account a growing literature that addresses the effectiveness of the interventions and whether modification or augmentative strategies may be beneficial.
CBT has been implemented in patients with PTSD and history of mild, moderate, and severe TBI, with positive treatment responses similar to those exhibited by patients with PTSD and no history of TBI and with no documented adverse events.
46–48 In a sample of PTSD patients who were undergoing CBT for PTSD-related insomnia and in which the majority (>75%) reported TBI history, less-proficient verbal memory was associated with mildly attenuated treatment response.
46 It is at least as likely that less-proficient verbal memory was associated with PTSD (and associated sleep problems) as opposed to TBI,
16 and similar relationships between verbal memory and CBT treatment response have been documented in PTSD patients without TBI.
49Among patients with TBI, CBT interventions targeting psychological trauma symptoms have also been effective in reducing symptoms of acute stress disorder,
50 depression,
48 and nonspecific postconcussive symptoms.
51 CBT treatment adherence among patients with PTSD and TBI, ranging from 22% to 53.7% in outpatient settings,
47,48 and up to 17% in inpatient/residential settings,
51,52 is comparable to that of patients with PTSD alone. Thus, although the research is still in its early stages, the available evidence suggests that CBT interventions commonly used to treat PTSD are both effective and safe in treating individuals with PTSD and TBI across a range of severities.
Little is known about the effects of modifying or augmenting PTSD interventions to accommodate co-occurring cognitive deficits or noncognitive neuropsychiatric symptoms. Regarding modification, there is currently no evidence that modifying either the delivery platform or core aspects of CBT interventions for PTSD results in superior outcomes in patients with TBI. In a small sample of veterans with comorbid PTSD and TBI, Wolf, Strom, Kehle, and Eftekhari
53 modified the delivery platform of prolonged exposure therapy to include external memory aides, increase the structure of session content, and extend the session time, and found that PTSD symptoms were successfully reduced. Because the modified version was not compared with unmodified delivery of the treatment, however, the effects of the modification could not be examined. In the context of a residential treatment program for comorbid TBI and PTSD, Walter, Dickstein, Barnes, and Chard
52 found that a version of cognitive processing therapy that omitted the writing of a trauma narrative to allow for more focus on cognitive interventions was successful in reducing symptoms of PTSD, depression, and other neuropsychiatric symptoms but did not demonstrate better outcomes when compared with standard implementation of cognitive processing therapy.
Regarding augmentation (i.e., adjunct interventions delivered in addition to PTSD interventions), results from a randomized controlled trial suggest that an intervention focused on psychoeducation and cognitive compensatory strategies (cognitive symptom management and rehabilitation therapy [CogSMART]) successfully reduced nonspecific affective symptoms in military veterans with TBI and PTSD.
54 However, empirical evaluation of the added value of augmentative strategies in patients with PTSD and TBI is still needed.
Pharmacological Treatment of PTSD and Implications for Comorbid TBI
At the time of this writing, there is limited empirical evidence with which to guide the pharmacological treatment of comorbid TBI and PTSD. In fact, treatment studies relevant to each condition generally exclude for the other condition. Here we overview psychopharmacological approaches to managing PTSD, taking into consideration potential implications arising from comorbid TBI. We also briefly review medications that are commonly used in the treatment of TBI and associated symptoms, but that may be contraindicated in PTSD.
Selective serotonin reuptake inhibitors (SSRIs) are recommended as first-line medications for the treatment of PTSD
55 based on the success of sertraline and paroxetine in large FDA registration trials. SSRIs may have the added benefit of targeting symptoms of common PTSD psychiatric comorbidities (e.g., depression, panic) and are recommended as first-line choice in treating depression associated with TBI.
56 Venlafaxine, which inhibits the reuptake of serotonin at lower doses, as well as norepinephrine at higher doses, also is a first-line pharmacological approach for treating PTSD, although venlafaxine has not been FDA-approved for this indication.
57–59 It is important, however, to consider that meta-analysis demonstrates only small to medium effect sizes for the difference in performance between SSRIs or SNRIs and placebo.
60 Thus, it may be difficult to discern whether symptom improvement in an individual patient is attributable to active drug, placebo effect, or other factors related to engagement in PTSD treatment.
The substantial rate of resistance to the potential therapeutic effect of SSRIs initially appeared to be related to male sex or veteran status; more recent overviews of SSRI treatment studies in PTSD suggest that resistance may be related to age, illness chronicity,
59 or possibly to ethnicity. Both SSRIs and venlafaxine are generally safe, although each may be associated with particular side effects. For example, agitation, insomnia, headache, sexual dysfunction, and increased bleeding risk may result from SSRI treatment (
Table 1); similar side effects may result from SNRIs due to their serotonin reuptake blocking properties.
61 Additionally, visual changes due to increased intraocular pressure, anxiety, dizziness, and increased heart rate or blood pressure may result from the norepinephrine reuptake blocking properties of SNRIs. Some of these side effects may be confused with symptoms of PTSD or TBI, especially when the TBI is relatively more severe.
As recently reviewed by Rasmusson et al.,
62 SSRIs at doses substantially below those that block serotonin reuptake increase the production of metabolites of progesterone (e.g., allopregnanolone) with anxiolytic, antidepressant, antiaggression, and anti-PTSD-like effects. Allopregnanolone potently facilitates the effects of gamma-amino-butyric acid (GABA) at brain GABA
A receptors and potently decreases the negative sequelae of brain ischemia and head trauma in rodent models.
63,64 Also as reviewed by Rasmusson et al.,
62 exposure to severe stress can reduce allopregnanolone levels in brain (e.g., prefrontal cortex) and the blood. Further, sex-specific deficits in the function of enzymes involved in allopregnanolone synthesis, and a negative relationship between severity of PTSD symptoms and levels of allopregnanolone and pregnanolone (a stereoisomer of allopregnanolone with equipotent effects at GABA
A receptors) have been demonstrated in women and men with PTSD. Thus, it is possible that deficits in allopregnanolone may be reversed by SSRIs in some individuals, but that some enzymatic blocks in allopregnanolone synthesis may not be reversible and contribute to the substantial rates of SSRI treatment resistance in PTSD and depression. These observations may be of particular relevance to individuals exposed to neurotrauma and chronic or traumatic stress simultaneously, such as survivors of physical assault or military personnel exposed to blasts from improvised explosive devices during the recent conflicts in Iraq and Afghanistan.
A number of medications other than SSRIs are used as second-line or augmentation approaches for the treatment of PTSD (see
Table 1). When symptoms of PTSD do not respond to treatment with an SSRI or SNRI, a tricyclic antidepressant or monoamine oxidase inhibitor may be considered. Research supporting the efficacy of these agents, however, is limited, and their administration can be accompanied by more significant side effects.
55A trial of bupropion, another antidepressant with dopamine and norepinephrine reuptake blocking properties, may be indicated if sexual dysfunction limits use of SSRIs or SNRIs. Bupropion may also be considered in the context of increased markers of inflammation (e.g., C-reactive protein) in association with anhedonia or psychomotor slowing. Inflammation effects on the synthesis, packaging, and release of dopamine, however, may limit the positive effects of bupropion and require novel approaches in the context of PTSD and TBI.
65Mirtazapine, an antidepressant that blocks serotonin type 2A (5HT
2A) receptors at low doses and norepinephrine reuptake at higher doses, may be especially advantageous in treating PTSD-comorbid depressive symptoms when used in conjunction with an SSRI.
66 Mirtazapine is associated with minimal side effects; drowsiness sometimes induced at lower doses of mirtazapine can be exploited in the treatment of PTSD-related insomnia.
Trazodone, another antidepressant with 5HT
2A blocking properties, also may be helpful in treating sleep disturbance associated with PTSD or possibly that induced by SSRI administration. Care must be taken, however, as a small but not insubstantial proportion of individuals demonstrate increased rates of CYP3A4 metabolism of trazodone to
meta-chlorophenylpiperazine (m-CPP),
67 a compound that releases serotonin and directly activates or antagonizes a broad range of serotonin receptors. In turn, m-CPP can induce intense anxiety, agitation, perceptual disturbances, hallucinations, headache, and anorexia.
68 Coadministration of SSRIs, which block the normal metabolism of m-CPP by the enzyme CYP2D6,
69 may further potentiate these side effects, which can easily be misconstrued as a worsening of PTSD, onset of a comorbid anxiety or psychotic disorder, or complications of TBI.
Finally, emerging evidence supports the efficacy of prazosin, a noradrenergic α
1 receptor inhibitor, as a treatment for insomnia due to trauma-related nightmares.
55 Meta-analytic review of six randomized controlled trials demonstrated that prazosin is efficacious in improving overall PTSD symptoms in addition to PTSD-related nightmares.
70 Relative to trazodone, prazosin is not sedating, although its use may be associated with headaches.
70Stimulants—sometimes prescribed for TBI—have been little studied in PTSD. A randomized, placebo-controlled pilot study found that patients with PTSD, history of TBI, or both responded positively to methylphenidate, a central nervous system stimulant commonly used to treat attention-deficit hyperactivity disorder (ADHD).
71 Patients tolerated methylphenidate well, reported fewer cognitive deficits as well as other postconcussive and PTSD symptoms, and showed improved performance on objective measures of attention and processing speed. This preliminary evidence suggests the need for further investigation of cognitive enhancing agents, which are not currently included in clinical practice guidelines, in the treatment of comorbid PTSD and TBI.
Several medication classes formerly considered as potential treatments for PTSD are not currently recommended, are contraindicated, or are used for only a narrow set of clinical presentations. These include benzodiazepines, antipsychotics, and anticonvulsants.
Benzodiazepines are not recommended in PTSD and, in general, are best avoided among persons with TBI given their sedating and amnestic effects as well as their adverse effects on motor function. Notably, benzodiazepines selectively target
synaptic GABA
A receptors, which have been shown to be downregulated in the amygdala after exposure to extreme stress. In contrast, low doses of alcohol and GABAergic neuroactive steroids such as allopregnanolone and ganaxolone also target
extrasynaptic GABA
A receptors, as does topiramate, perhaps accounting for the impact of allopregnanolone and ganaxolone on PTSD-like behaviors in rodent models
62 and topiramate on PTSD symptoms in humans.
72Conventional antipsychotics with primary antagonistic effects at dopamine type 2 receptors are also contraindicated in PTSD treatment. Atypical antipsychotics that antagonize 5HT
2A receptors, and often noradrenergic α
1 receptors as well, are generally not recommended unless the patient is presenting with psychotic or dissociative symptoms not attributable to another disorder (e.g., delirium, dementia); atypical antipsychotics may also be considered in patients presenting with extreme hypervigilance/paranoia, aggression, and social isolation that have not responded to treatment with other medications.
55Anticonvulsants, a medication class potentially prescribed to prevent or treat seizures in patients with moderate to severe TBI, are typically not recommended for use in PTSD outside the context of TBI due to insufficient demonstration of their efficacy versus side effect profile
55; anticonvulsants, however, are not contraindicated in PTSD if necessary for treatment of seizures associated with comorbid TBI.
In summary, the available evidence suggests that the pharmacological treatment of PTSD in patients with comorbid TBI is best approached similarly to that of PTSD alone. Many of the medication side effects relevant to TBI are also relevant to PTSD, although the risk of certain side effects may be especially concerning in patients with comorbid PTSD and TBI, as they may be even more vulnerable to medication-induced exacerbation of symptoms or side effects (e.g., agitation/insomnia/ impulsivity and risk of self-/other harm). The general consensus in prescribing to patients with PTSD and TBI history is to start with low doses and titrate slowly; be cognizant of possible drug interactions; and use caution when potential medication side effects might increase risk of TBI-associated problems, such as cognitive deficits, sensory and balance issues, and seizures.
73 In the meantime, research is evolving to focus on development of new treatments and the precision medicine targeting of such treatments to pathological processes that contribute to PTSD and TBI risk, severity, and chronicity at the individual patient level.